Management of Acute Proliferative Diabetic Retinopathy Related Complications During the First COVID-19 Wave

Overview

Journal BMC Ophthalmol

Publisher Biomed Central

Specialty Ophthalmology

Date 2022 Mar 13

PMID 35279117

Authors

Niku Dhillon

Cynthia Santiago

Affiliations

Soon will be listed here.

Abstract

Background: Routine hospital eye services (HES) across the National health service (NHS), and diabetic eye screening (DES) in Scotland were paused during the COVID-19 lockdown in March 2020. Alternate pathways for managing acute ophthalmic pathology were devised in NHS Grampian covering the North-East of Scotland. Emergency eye treatment centres (EETC) manned by community optometrists were set up to treat and triage referrals to HES.

Methods: Retrospective study analysing consecutive patients referred to a tertiary eye centre (Aberdeen Royal Infirmary) with proliferative diabetic retinopathy (PDR) related complications between March and August 2020. General demographical data, diabetic history, visual acuity, ocular complication, type of management, time to follow-up, and any appointment cancellations were extracted for analysis.

Results: Fifty two eyes of 46 patients with PDR related complications were identified. HES appointment had been delayed or cancelled in 22 patients (48%) due to COVID-19. Mean age was 54.5 years (±15.1), 21 (46%) were female, 21 (46%) had type 1 diabetes; mean HbA1c was 78 mmol/l (±18.7). Vision ranged from 6/6 to perception of light. 36 (78%) patients had unilateral vitreous haemorrhage (VH), 6 (13%) bilateral, 2 (4%) tractional retinal detachments and 3 (6.5%) had neovascular glaucoma. Of 48 acute PDR presentations, 18 (38%) were given anti-VEGF within 72 h and two (4%) had PRP the same day. 16 (33%) were rebooked into the laser clinic, 13 (27%) referred for urgent surgical review, and 17 (35%) advised observation and review in clinic. After a median follow-up of 6 months, 12 eyes (23%) of 11 patients progressed to have vitrectomy.

Conclusion: Despite lockdown, hospital appointment cancellations and recommended footfall reduction limiting capacity due to COVID-19, patients reaching out with PDR complications were promptly referred to HES and appropriate treatments carried out with COVID-19 precautions as recommended.

Citing Articles

Research progress on ocular complications caused by type 2 diabetes mellitus and the function of tears and blepharons.

Wang X, Fang J, Yang L Open Life Sci. 2024; 19(1):20220773.

PMID: 38299009 PMC: 10828665. DOI: 10.1515/biol-2022-0773.

Proliferative Diabetic Retinopathy Requiring Vitrectomy Over Clinic Management During COVID-19: Impact of Delayed Care.

Ahearn B, Nguyen H, Sohn J Korean J Ophthalmol. 2023; 37(4):292-298.

PMID: 37336513 PMC: 10427906. DOI: 10.3341/kjo.2022.0147.

References

Russo A, Longo A, Avitabile T, Bonfiglio V, Fallico M, Boscia F . Incidence and Risk Factors for Tractional Macular Detachment after Anti-Vascular Endothelial Growth Factor Agent Pretreatment before Vitrectomy for Complicated Proliferative Diabetic Retinopathy. J Clin Med. 2019; 8(11). PMC: 6912392. DOI: 10.3390/jcm8111960. View

Fernandez E, Cortazar A, Bellido V . Impact of COVID-19 lockdown on glycemic control in patients with type 1 diabetes. Diabetes Res Clin Pract. 2020; 166:108348. PMC: 7375311. DOI: 10.1016/j.diabres.2020.108348. View

Syriga M, Karampela I, Dalamaga M, Karampelas M . The effect of COVID-19 pandemic on the attendance and clinical outcomes of patients with ophthalmic disease: A mini-review. Metabol Open. 2021; 12:100131. PMC: 8474871. DOI: 10.1016/j.metop.2021.100131. View

Yorston D, Wickham L, Benson S, Bunce C, Sheard R, Charteris D . Predictive clinical features and outcomes of vitrectomy for proliferative diabetic retinopathy. Br J Ophthalmol. 2008; 92(3):365-8. DOI: 10.1136/bjo.2007.124495. View

Ghosal S, Sinha B, Majumder M, Misra A . Estimation of effects of nationwide lockdown for containing coronavirus infection on worsening of glycosylated haemoglobin and increase in diabetes-related complications: A simulation model using multivariate regression analysis. Diabetes Metab Syndr. 2020; 14(4):319-323. PMC: 7146694. DOI: 10.1016/j.dsx.2020.03.014. View

Song W, Singh R, Rachitskaya A . The Effect of Delay in Care among Patients Requiring Intravitreal Injections. Ophthalmol Retina. 2021; 5(10):975-980. DOI: 10.1016/j.oret.2020.12.020. View

Ghasemi Falavarjani K, Nguyen Q . Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013; 27(7):787-94. PMC: 3709385. DOI: 10.1038/eye.2013.107. View

Safadi K, Kruger J, Chowers I, Solomon A, Amer R, Aweidah H . Ophthalmology practice during the COVID-19 pandemic. BMJ Open Ophthalmol. 2020; 5(1):e000487. PMC: 7222613. DOI: 10.1136/bmjophth-2020-000487. View

. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol. 2013; 131(3):283-93. PMC: 4217122. DOI: 10.1001/jamaophthalmol.2013.2015. View

10.

Park Y, Ahn J, Kim T, Park S, Joo K, Park K . Efficacy of bevacizumab for vitreous haemorrhage in proliferative diabetic retinopathy with prior complete panretinal photocoagulation. Eye (Lond). 2021; 35(11):3056-3063. PMC: 8526678. DOI: 10.1038/s41433-020-01384-y. View

11.

Chatziralli I, Dimitriou E, Kazantzis D, Machairoudia G, Theodossiadis G, Theodossiadis P . Effect of COVID-19-Associated Lockdown on Patients With Diabetic Retinopathy. Cureus. 2021; 13(5):e14831. PMC: 8173491. DOI: 10.7759/cureus.14831. View

12.

Alshareef R, Al Zahrani A, Alzahrani A, Ghandoura L . Impact of the COVID-19 lockdown on diabetes patients in Jeddah, Saudi Arabia. Diabetes Metab Syndr. 2020; 14(5):1583-1587. PMC: 7422800. DOI: 10.1016/j.dsx.2020.07.051. View

13.

Gross J, Glassman A, Jampol L, Inusah S, Aiello L, Antoszyk A . Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA. 2015; 314(20):2137-2146. PMC: 5567801. DOI: 10.1001/jama.2015.15217. View

14.

Gao S, Lin Z, Shen X . Anti-Vascular Endothelial Growth Factor Therapy as an Alternative or Adjunct to Pan-Retinal Photocoagulation in Treating Proliferative Diabetic Retinopathy: Meta-Analysis of Randomized Trials. Front Pharmacol. 2020; 11:849. PMC: 7289996. DOI: 10.3389/fphar.2020.00849. View

15.

Antoszyk A, Glassman A, Beaulieu W, Jampol L, Jhaveri C, Punjabi O . Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA. 2020; 324(23):2383-2395. PMC: 7739132. DOI: 10.1001/jama.2020.23027. View

16.

He F, Yu W . Longitudinal neovascular changes on optical coherence tomography angiography in proliferative diabetic retinopathy treated with panretinal photocoagulation alone versus with intravitreal conbercept plus panretinal photocoagulation: a pilot study. Eye (Lond). 2019; 34(8):1413-1418. PMC: 7376016. DOI: 10.1038/s41433-019-0628-3. View

17.

Ferrara M, Romano V, Steel D, Gupta R, Iovino C, van Dijk E . Reshaping ophthalmology training after COVID-19 pandemic. Eye (Lond). 2020; 34(11):2089-2097. PMC: 7329193. DOI: 10.1038/s41433-020-1061-3. View

18.

Flynn Jr H, Chew E, Simons B, Barton F, Remaley N, Ferris 3rd F . Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1992; 99(9):1351-7. DOI: 10.1016/s0161-6420(92)31779-8. View

19.

Forster A, Forbes A, Dodhia H, Connor C, du Chemin A, Sivaprasad S . Non-attendance at diabetic eye screening and risk of sight-threatening diabetic retinopathy: a population-based cohort study. Diabetologia. 2013; 56(10):2187-93. DOI: 10.1007/s00125-013-2975-0. View

20.

Looker H, Nyangoma S, Cromie D, Olson J, Leese G, Black M . Rates of referable eye disease in the Scottish National Diabetic Retinopathy Screening Programme. Br J Ophthalmol. 2014; 98(6):790-5. PMC: 4033179. DOI: 10.1136/bjophthalmol-2013-303948. View